The Boston Biotech Survival Index: Big Fish Still Swimming, Minnows Getting Eaten

10/8/09Follow @xconomy

New England has a deep pond with many of the very biggest fish in the global life sciences industry, but it also has its share of minnows, and they are getting eaten alive in the downturn.

That finding leaped out at me after I scoured through financial data on 85 publicly traded life sciences companies in greater Boston, Seattle, and San Diego as part of our regular Biotech Survival Index feature. The final numbers aren’t pretty for Boston. Just 15 of the 46 public life sciences companies we follow in Massachusetts had more cash on their balance sheet at the end of June 2009 than they did on New Year’s Day, based on a review of the most recent round of quarterly financial filings with the Securities and Exchange Commission. (Companies were included if they were listed on the NASDAQ or NYSE, and had market capitalization of at least $100 million).

Even though jobs have been cut, drug candidates have been shelved, and some last-ditch partnerships have been struck, all that frenzied activity didn’t really add up to a strengthened financial future for a majority of the region’s money-losing companies. The cash crunch has prompted a couple of Massachusetts companies to fold this year (Altus Pharmaceuticals and Epix Pharmaceuticals), a couple more to sell out for a pittance (Targanta Therapeutics and NitroMed), and one company that actually improved its financial position to move to Wisconsin (Exact Sciences).

While those companies were vanishing, there was some good news to be found in the filings. Some of Boston’s anchor tenants took advantage of their financial strength to beef up their cash balances, pay down debt, or otherwise tidy up financial matters. Essentially, the rich (Biogen Idec, Genzyme, Thermo Fisher Scientific, and Millipore, to name a few) got richer.

But what really shocked me the most was how poorly Boston’s life sciences companies have coped with the downturn compared with peers in the two other cities where Xconomy follows life sciences—Seattle and San Diego. Granted, neither of those cities has anywhere near the number of profitable life sciences companies that Boston does (18). And many of the little biotechs in those cities were backed into a corner in the first half of 2009, and either had to do or die—and things don’t appear quite that dire yet at many companies in Boston. But a majority of companies in Seattle (7 of 12) actually strengthened their balance sheets during the first half of the year. The same pattern emerged in San Diego, where 15 of the 27 companies built up their cash reserves in the same period.

If you combine those two hubs into a West Coast cluster that has a sample size similar to Boston’s (39 companies versus 46), the Bay State doesn’t look so resilient in comparison. About 56 percent of companies on the West Coast (22 of 39) strengthened their financial position in the first half of the year, while just 33 percent of the companies in Boston (15 of 46) did that well.

Read on for a complete rundown of the financial position for all 46 Massachusetts companies, listed in alphabetical order. To purchase a much expanded version of this report, in PDF format, click the “Add to Cart” button below. The expanded version, available for $95,* includes an assessment of each company’s financial position at the end of June compared to six months earlier, the projected length of time it can survive on its existing cash reserves, and an analysis of the strategic moves it has made to stay afloat in the current environment. Click here to see a sample entry. *Price is subject to change without notice.

Add to Cart

We intend to repeat this analysis regularly to monitor the financial health of the life sciences companies we follow in San Diego, Seattle, and Boston. Please send feedback to editors@xconomy.com.

Abiomed (NASDAQ: ABMD)
Cash on hand: $54.5 million
Related Xconomy coverage:
Abiomed Wins FDA Approval of Heart Pump

Alkermes (NASDAQ: ALKS)
Cash on hand: $380.4 million
Related Xconomy coverage:
Alkermes Knocks on Door of Biotech Big Leagues, Aims to Make Drugs of its Own
Alkermes, Swinging for the Fence, Touts New Anti-Addiction Drug
Alkermes’ Ambitious Builder, Richard Pops, Grabs Reins to Re-Ignite Growth Phase

Alnylam Pharmaceuticals (NASDAQ: ALNY)
Cash on hand: $473.8 million
Related Xconomy coverage:
Alnylam Takes Time to Mull Over RSV Game Plan
Alnylam, With Tekmira and New Northwest Firm Alcana, Look to Push Borders of RNAi Delivery
Alnylam Pushes First RNAi Drug That Circulates Through Body Into Human Test
Alnylam’s In the Money, Expects $500 Million in Bank At Year End
Alnylam Looks to Spinoffs to Unleash RNAi Technologies for Stem Cells, Vaccines

Altus Pharmaceuticals (NASDAQ: ALTU)
Cash on hand
: $8.1 million
Related Xconomy coverage:
Altus Pharma to Shut Doors
Altus Cuts 75 Percent of Staff

AMAG Pharmaceuticals (NASDAQ: AMAG)
Cash on hand: $175 million
Related Xconomy coverage:
AMAG Pharmaceuticals Wins FDA Approval to Sell Iron Deficiency Drug

Antigenics (NASDAQ: AGEN)
Cash on hand: $21.1 million
Related Xconomy coverage:
Riding Dendreon’s Coattails, Antigenics and Oncothyreon Shares Soar
Antigenics, Digging Through Old Data, Sees Survival Edge For Cancer Vaccine
Antigenics Asks European Regulators to Approve Oncophage For Kidney Cancer

Ariad Pharmaceuticals (NASDAQ: ARIA)
Cash on hand: $39.5 million
Related Xconomy coverage:
Ariad Directors Resign En Masse, Accuse CEO of Grossly Inappropriate Behavior
Ariad Pharmaceuticals Edging Toward Becoming a Commercial Cancer Drug Company
Ariad CEO Fires Back at Resigning Directors and Their ‘False and Misleading’ Attacks
Ariad Raises $30.9M

ArQule (NASDAQ: ARQL)
Cash on hand: $185.7 million
Related Xconomy coverage:
ArQule Snags $60M From Daiichi Sankyo
ArQule Gets a New CEO”

To purchase a much expanded version of this report, in PDF format, click the “Add to Cart” button.
For $95,* you’ll get an assessment of each company’s financial position at the end of June compared to six months earlier, the projected length of time it can survive on its existing cash reserves, and an analysis of the strategic moves it has made to stay afloat in the current environment. Click here to see a sample entry. Add to Cart
*Price is subject to change without notice

Biogen Idec (NASDAQ: BIIB)
Cash on hand
: $1.62 billion
Related Xconomy coverage
:
Biogen Idec Makes Hostile $350M Takeover Bid for Facet Biotech
Icahn Throws Down the Gloves, Attacks Biogen Idec’s ‘Failed Leadership‘”
Biogen Idec Pipeline Strong, Tysabri Coming Back, Icahn Would Weaken Board, Company Says
Biogen Idec Research Boss Quits Board, Giving Icahn Shot at Pushing R&D Agenda
Biogen Idec Tysabri Sales Fall Shy of Street Expectations

Boston Scientific (NYSE: BSX)
Cash on hand: $1.19 billion
Related Xconomy coverage:
Boston Scientific CEO Retires, Replaced By Former Zimmer Boss
Boston Scientific Pays $716M to Settle Patent Dispute With J&J

Bruker (NASDAQ: BRKR)
Cash on hand: $152.6 million

Caliper Life Sciences (NASDAQ: CALP)
Cash on hand: $23.5 million
Related Xconomy coverage
:
Caliper Bets Future on Tools That Light Up Genes Before Researchers’ Eyes

Celldex Therapeutics (NASDAQ: CLDX)
Cash on hand: $31.6 million
Related Xconomy coverage:
Avant Changes Name to Celldex Therapeutics, Hires Marucci as Permanent CEO

Charles River Labs (NYSE: CRL)
Cash on hand: $154.8 million

Clinical Data (NASDAQ: CLDA)
Cash on hand: $52.4 million
Related Xconomy coverage:
Clinical Data Touts Positive Results for Anti-Depressant

CombinatoRx (NASDAQ:CRXX)
Cash on hand: $26.5 million
Related Xconomy coverage:
Former CEO Alexis Borisy Voices Mixed Feelings on CombinatoRx Saga
CombinatoRx Judgment Day Coming Soon, Arthritis Drug Results on the Way
CombinatoRx To Combine With Neuromed

Cubist Pharmaceuticals (NASDAQ: CBST)
Cash on hand: $474.4 million
Related Xconomy coverage:
Alnylam, Cubist Will Cooperate on RNAi Drug for Lung Infections
Cubist Agrees to Promote AstraZeneca Antibiotic

Curis (NASDAQ: CRIS)
Cash on hand: $26.8 million
Related Xconomy coverage:
Curis Gets $3M from Genentech for Ovarian Cancer Trial Initiation

Dyax (NASDAQ: DYAX)
Cash on hand: $53.1 million
Related Xconomy coverage:
Dyax Hit With FDA Drug Delay
Dyax Lands Deal to Raise $50M
FDA Committee Votes in Favor of Dyax Lead Drug for Rare Blood Disease

Genzyme (NASDAQ: GENZ)
Cash on hand: $1.05 billion
Related Xconomy coverage:
Genzyme Says Supplies of Two Enzyme Drugs Will Be Even Lower Than Previously Predicted
Genzyme’s Woes Piling Up as FDA Panel Says Data on Leukemia Drug Are Lacking
Genzyme Offers Glimpse at Growth Engine, New Drugs for High Cholesterol, Gaucher’s
Genzyme Halts Production at Allston Drug Plant After Virus Appears
Genzyme Reaching for a Slice From Biogen’s Breadbasket, Multiple Sclerosis Drugs

GTC Biotherapeutics (NASDAQ: GTCB)
Cash on hand: $4.7 million
Related Xconomy coverage:
FDA Approves First Drug Made From Bioengineered Goats
GTC Biotherapeutics Racing Against Time To Prove The Worth of Pharming, Thinks It Has the Edge

Haemonetics (NYSE: HAE)
Cash on hand: $173.8 million

To purchase a much expanded version of this report, in PDF format, click the “Add to Cart” button.
For $95,* you’ll get an assessment of each company’s financial position at the end of June compared to six months earlier, the projected length of time it can survive on its existing cash reserves, and an analysis of the strategic moves it has made to stay afloat in the current environment. Click here to see a sample entry. Add to Cart
*Price is subject to change without notice

Harvard Bioscience (NASDAQ: HBIO)
Cash on hand: $16.8 million

Helicos Biosciences (NASDAQ: HLCS)
Cash on hand: $8.4 million
Related Xconomy coverage:
Helicos Biosciences, Running Low on Cash, Snaps Up $10M Lifeline
With New Machine, Helicos Brings Personal Genome Sequencing a Step Closer
Helicos Cuts 30 Percent of Workforce
Helicos Shuffles CEOs, Names Lowy to Top Job

Hologic (NASDAQ: HOLX)
Cash on hand: $243.7 million
Related Xconomy coverage:
Third Wave Means Extra Power for Hologic

Idenix Pharmaceuticals (NASDAQ: IDIX)
Cash on hand: $51.7 million
Related Xconomy coverage:
Idenix Inks HIV Drug Deal With GSK Worth Up To $450M

Idera Pharmaceuticals (NASDAQ: IDRA)
Cash on hand: $50.5 million
Related Xconomy coverage:
Idera and Merck Extend R&D Deal
Idera Pharmaceuticals Inks Potential $400 Million Deal With Germany’s Merck

ImmunoGen (NASDAQ: IMGN)
Cash on hand: $71.1 million
Related Xconomy coverage:
Souped Up Herceptin Aims to Validate Immunogen’s Long Sought Dream Cancer Drug
ASCO Weekend Highlights, Immunogen, Antigenics, Aveo Show Off Cancer Drug Findings

Infinity Pharmaceuticals (NASDAQ: INFI)
Cash on hand: $150.4 million
Related Xconomy coverage:
Infinity Sees Comeback Potential for Cancer Drug That Failed
Infinity Pharma Lead Cancer Drug Trial Ends in Failure
Infinity Snags $75 Million Through Alliance With Purdue Pharma and Mundipharma

Insulet (NASDAQ: PODD)
Cash on hand: $52.3 million
Related Xconomy coverage:
The Greater Boston Diabetes Cluster

Inverness Medical Innovations (NYSE: IMA)
Cash on hand: $425.5 million
Related Xconomy coverage:
Inverness to Raise $200M in Notes Sale

Javelin Pharmaceuticals (AMEX: JAV)
Cash on hand: $7.3 million
Related Xconomy coverage:
Javelin Pharma Stock Takes Hit

Millipore (NYSE: MIL)
Cash on hand: $146.6 million
Related Xconomy coverage:
Millipore Buys Guava

Molecular Insight Pharmaceuticals (NASDAQ: MIPI)
Cash on hand: $82.9 million
Related Xconomy coverage:
Imaging Agent for Early Detection of Heart Disease From Molecular Insight Reaches Goal

Momenta Pharmaceuticals (NASDAQ: MNTA)
Cash on hand: $72.1 million
Related Xconomy coverage:
Momenta Pharma Competitor Lodges Ethics Complaint Against FDA Boss, WSJ Reports
Momenta Gets Some Mojo as FDA Agrees to Review Application of Generic MS Drug

NxStage Medical (NASDAQ: NXTM)
Cash on hand: $24.5 million
Related Xconomy coverage:

Parexel International (NASDAQ: PRXL)
Cash on hand: $96.3 million
Related Xconomy coverage:
Parexel to Purchase Clinphone for $182M

To purchase a much expanded version of this report, in PDF format, click the “Add to Cart” button.
For $95,* you’ll get an assessment of each company’s financial position at the end of June compared to six months earlier, the projected length of time it can survive on its existing cash reserves, and an analysis of the strategic moves it has made to stay afloat in the current environment. Click here to see a sample entry. Add to Cart
*Price is subject to change without notice

PerkinElmer (NYSE: PKI)
Cash on hand: $151.3 million
Related Xconomy coverage:
PerkinElmer Sacrifices Short Term Profits to Preserve R&D, Buy Technologies on the Cheap

Repligen (NASDAQ: RGEN)
Cash on hand: $62 million
Related Xconomy coverage:
Repligen BMS Settle Patent Suit

RXi Pharmaceuticals (NASDAQ: RXII)
Cash on hand: $4.4 million
Related Xconomy coverage:
RXi Announces $8.3M Offering
Oral RNAi Drug Stops Inflammation in Mice, RXi Says
RXi Eyes a Future of RNAi Drugs You Take as Oral Pills
Alnylam, RXi on Collision Course Over Intellectual Property From Massachusetts Life Sciences Initiative
RXi Takes an Untraditional Route to the Public Market, Now Working to Get Pharma to Pay the Bills

Sepracor (NASDAQ: SEPR)
Cash on hand: $707.2 million
Related Xconomy coverage:
Drugmaker Sepracor Accepts $2.6B Buyout Offer From Japan’s Dainippon

Synta Pharmaceuticals (NASDAQ:SNTA)
Cash on hand: $60.5 million
Related Xconomy coverage:
Glaxo Ends Synta Partnership
Synta Melanoma Drug Disastrously in Clinical Trial as Patients Show Higher Death Rate
Synta, Developer of New Class of Cancer Drugs, Eagerly Awaits Results From Key Trial

Thermo Fisher Scientific (NYSE: TMO)
Cash on hand: $1.43 billion
Related Xconomy coverage:
Thermo Fisher Names New CEO

Vertex Pharmaceuticals (NASDAQ: VRTX)
Cash on hand: $754.4 million
Related Xconomy coverage:
Vertex Drug Could Be Man Walking on the Moon for Cystic Fibrosis, Says Seattle Researcher Bonnie Ramsey
Vertex Acquires Virochem for $375M to Make Cocktail Treatments for Hepatitis C
Vertex Fending Off Competitors By Treating the Toughest Patients With Hepatitis C
Vertex CEO Josh Boger Retiring in May, Matthew Emmens to Fill Role
Out With the Hedge Funds, In With Blue Bloods, Vertex Transforms Investor Base Via Stock Sale

Waters (NYSE: WAT)
Cash on hand: $505.7 million

Zoll Medical (NASDAQ: ZOLL)
Cash on hand: $55.3 million
Related Xconomy coverage:
Zoll Medical to Buy Alsius for $12m

By posting a comment, you agree to our terms and conditions.